Normunity Raises $65M in Series A Financing

Normunity

Normunity, a Boston, MA and West Haven, CT-based biotechnology company, raised $65M in Series A funding.

The round was led by Canaan Ventures with participation from Sanofi Ventures, Taiho Ventures and Osage University Partners.

The company intends to use the funds to advance its emerging pipeline of immune normalizers into the clinic. Proceeds from the financing will also be used to build on multiple discovery platforms in the Lieping Chen lab to pursue additional mechanisms that block normal anti-cancer immunity. 

Led by Rachel Humphrey, MD, founding Chief Executive Officer, Normunity is a biotechnology company creating a new class of immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system.

FinSMEs

26/10/2022